MISC

2003年6月

Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer

LUNG CANCER
  • Okamoto, I
  • ,
  • K Fujii
  • ,
  • M Matsumoto
  • ,
  • Y Terasaki
  • ,
  • N Kihara
  • ,
  • H Kohrogi
  • ,
  • M Suga

40
3
開始ページ
339
終了ページ
342
記述言語
英語
掲載種別
DOI
10.1016/S0169-5002(03)00043-6
出版者・発行元
ELSEVIER SCI IRELAND LTD

ZD 1839 is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). We now present a case of diffuse alveolar damage (DAD) that developed in a 67-year-old man treated with ZD1839. On day 8 of ZD1839 administration, the patient complained of dyspnea and a new-ground glass opacity was apparent on a chest X-ray and computed tomography scan. Despite high-dose steroid therapy, the patient died 13 days after the first administration of ZD1839. Postmortem analysis of lung tissue revealed a pattern of DAD. No evidence of infection or of other specific etiologies was apparent. This case is the first reported of respiratory failure after ZD1839 treatment in a patient with NSCLC. Physicians should therefore be aware of the potential pulmonary toxicity of ZD1839. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/S0169-5002(03)00043-6
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000183391800014&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/S0169-5002(03)00043-6
  • ISSN : 0169-5002
  • Web of Science ID : WOS:000183391800014

エクスポート
BibTeX RIS